Capricor Therapeutics, Inc. (CAPR) Stock Grade

About Capricor Therapeutics, Inc.'s fundamentals

Capricor Therapeutics is a biotechnology company with a market capitalization of $500.9M that is currently unprofitable, having reported a net loss in its latest annual statement with a net margin of 0.0%. The company shows negative revenue growth of -100.0% year-over-year, indicating it generated no product revenue during the period. The company does not pay a dividend, and standard valuation metrics like P/E ratio and return on equity are not applicable given the loss-making status. As a development-stage biotech firm, Capricor's financial performance reflects the typical profile of companies in early commercialization or pre-revenue phases.